ArticleStem cells international2026
The Oncogenic Role of Serum Marker GDF15 in Promoting Colorectal Tumorigenesis via EMT and Stemness.
Article in Stem cells international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Oncogenic Role of Serum Marker GDF15 in Promoting Colorectal Tumorigenesis via EMT and Stemness.Stem cells international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Growth Differentiation Factor 15 (GDF15), a stress-responsive cytokine, is involved in the progression of various cancers. However, its precise functional role and underlying mechanism in colorectal cancer (CRC) remain unclear. Methods: GDF15 expression in CRC was analyzed using public databases and validated in patient tissues by Western blot. Functional assays, including colony formation, CCK-8, wound-healing, and Transwell, were performed on LOVO and HCT116 cells following GDF15 overexpression or knockdown to assess proliferation, migration, and invasion. Epithelial-mesenchymal transition (EMT) and stemness markers were examined by Western blot. Cancer stem cell properties were evaluated using a tumorsphere formation assay. Results: GDF15 was significantly upregulated in CRC tissues at both mRNA and protein levels. In vitro, GDF15 overexpression in LOVO cells promoted proliferation, migration, and invasion and induced EMT, as evidenced by downregulated E-cadherin and upregulated vimentin and N-cadherin. Conversely, GDF15 knockdown in HCT116 cells produced opposite effects. Furthermore, GDF15 enhanced CRC cell stemness, increasing tumorsphere formation and upregulating stemness markers (CD133, SALL4, OCT4, NANOG). Clinically, high serum GDF15 levels were significantly associated with advanced age, late TNM stage, and elevated CEA, indicating its correlation with aggressive disease features. Conclusion: Our findings demonstrate that GDF15 acts as a tumor promoter in CRC by driving EMT, facilitating proliferation and metastasis, and enhancing cancer stemness. This study identifies GDF15 as a potential biomarker and therapeutic target for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.